A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus

Completed · Phase 1 · Has a placebo group

Conditions studied: Diabetes Mellitus, Type 1

In brief

The main purpose of this study is to evaluate the response of glucagon to insulin-induced low blood sugar after administration of the study drug LY3532226 in participants with type 1 diabetes mellitus (T1DM). The study will also evaluate if LY3532226 helped participants to recover from insulin-induced low blood sugar condition compared to placebo. The study will last approximately 16 weeks excluding screening period.

Key facts

Study ID

NCT05887999

Run by

Eli Lilly and Company

People needed

30

Starts

2023-06-12

Expected to finish

2024-02-21

Last updated by the study team

2024-03-26

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with type 1 diabetes mellitus (T1DM) for at least 2 years treated with insulin
• Body mass index (BMI) of 18.5 to 40.0 kilograms per meter squared (kg/m²)
• Are males or females not of childbearing potential

You may not qualify if…

• Have acute proliferative retinopathy requiring active treatment within 3 months of screening
• Have been treated with dipeptidyl peptidase-Ni, GLP-1 receptor agonists, GIP agonists, metformin or sodium-glucose cotransporter 2 inhibitors within the previous 3 months
• Have received systemic or inhaled glucocorticoid therapy
• Women of childbearing potential
• Are currently taking part in another clinical study trial involving medical research, or have participated within the last 30 days of screening in a clinical study involving a study intervention

Where it is running

• ProSciento, Inc — Chula Vista, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.